Skip to main content

Advertisement

SpringerLink
Log in

Sustained Remission Over 36 Months of Advanced Hepatocellular Carcinoma After Short-Term Sorafenib Therapy

  • Case Report
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576.

    Article  PubMed  CAS  Google Scholar 

  2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.

    Article  PubMed  CAS  Google Scholar 

  3. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

    Article  PubMed  CAS  Google Scholar 

  4. Irtan S, Chopin-Laly X, Ronot M, Faivre S, Paradis V, Belghiti J. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int Off J Int Assoc Study Liver. 2011;31:740–743.

    Article  Google Scholar 

  5. Curtit E, Thiery-Vuillemin A, Nguyen T, et al. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:e330–e332.

    Article  Google Scholar 

  6. So BJ, Bekaii-Saab T, Bloomston MA, Patel T. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. J Hematol Oncol. 2008;1:18.

    Article  PubMed  Google Scholar 

  7. Kudo M, Ueshima K. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology. 2010;78(Suppl 1):154–166.

    Article  PubMed  CAS  Google Scholar 

  8. Wang SX, Byrnes A, Verma S, Pancoast JR, Rixe O. Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. Target Oncol. 2010;5:59–63.

    Article  PubMed  Google Scholar 

  9. Inuzuka T, Nishikawa H, Sekikawa A, et al. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. Oncology. 2011;81:152–157.

    Article  PubMed  Google Scholar 

  10. Chelis L, Ntinos N, Souftas V, et al. Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: possible synergy with HAART? A case report. Med Oncol. 2011;28:S165–s168.

    Article  PubMed  Google Scholar 

  11. Sacco R, Bargellini I, Gianluigi G, et al. Complete response for advanced liver cancer during sorafenib therapy: case report. BMC Gastroenterol. 2011;11:4.

    Article  PubMed  CAS  Google Scholar 

  12. Yeganeh M, Finn RS, Saab S. Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transpl Off J Am Soc Transpl Am Soc Transp Surg. 2009;9:2851–2854.

    CAS  Google Scholar 

  13. Yau T, Yao TJ, Chan P, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 2011;16:1270–1279.

    Article  PubMed  CAS  Google Scholar 

  14. Novi M, Lauritano EC, Piscaglia AC, et al. Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am J Gastroenterol. 2009;104:1852–1854.

    Article  PubMed  Google Scholar 

  15. Oquinena S, Guillen-Grima F, Inarrairaegui M, Zozaya JM, Sangro B. Spontaneous regression of hepatocellular carcinoma: a systematic review. Eur J Gastroenterol Hepatol. 2009;21:254–257.

    Article  PubMed  Google Scholar 

  16. Takeda Y, Togashi H, Shinzawa H, et al. Spontaneous regression of hepatocellular carcinoma and review of literature. J Gastroenterol Hepatol. 2000;15:1079–1086.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Kyungpook National University, Daegu, Republic of Korea

    Sun Young Ahn, Hyun Seok Lee, Young Oh Kweon, Won Young Tak & Soo Young Park

Authors
  1. Sun Young Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hyun Seok Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Young Oh Kweon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Won Young Tak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Soo Young Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Soo Young Park.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahn, S.Y., Lee, H.S., Kweon, Y.O. et al. Sustained Remission Over 36 Months of Advanced Hepatocellular Carcinoma After Short-Term Sorafenib Therapy. Dig Dis Sci 58, 1428–1432 (2013). https://doi.org/10.1007/s10620-012-2522-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2522-8

Keywords

Search

Navigation